Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. 2011

O Reynard, and V Mokhonov, and E Mokhonova, and J Leung, and A Page, and M Mateo, and O Pyankova, and M C Georges-Courbot, and H Raoul, and A A Khromykh, and V E Volchkov
Filovirus Laboratory, INSERM U758, Human Virology Department, Claude Bernard University Lyon-1, Université de Lyon, Ecole Normale Supérieure de Lyon, Lyon, France.

Pre- or postexposure treatments against the filoviral hemorrhagic fevers are currently not available for human use. We evaluated, in a guinea pig model, the immunogenic potential of Kunjin virus (KUN)-derived replicons as a vaccine candidate against Ebola virus (EBOV). Virus like particles (VLPs) containing KUN replicons expressing EBOV wild-type glycoprotein GP, membrane anchor-truncated GP (GP/Ctr), and mutated GP (D637L) with enhanced shedding capacity were generated and assayed for their protective efficacy. Immunization with KUN VLPs expressing full-length wild-type and D637L-mutated GPs but not membrane anchor-truncated GP induced dose-dependent protection against a challenge of a lethal dose of recombinant guinea pig-adapted EBOV. The surviving animals showed complete clearance of the virus. Our results demonstrate the potential for KUN replicon vectors as vaccine candidates against EBOV infection.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014613 Vaccines, Attenuated Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. Attenuated Vaccine,Vaccines, Live, Attenuated,Attenuated Vaccines,Vaccine, Attenuated
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic
D014902 West Nile virus A species of FLAVIVIRUS, one of the Japanese encephalitis virus group (ENCEPHALITIS VIRUSES, JAPANESE). It can infect birds and mammals. In humans, it is seen most frequently in Africa, Asia, and Europe presenting as a silent infection or undifferentiated fever (WEST NILE FEVER). The virus appeared in North America for the first time in 1999. It is transmitted mainly by CULEX spp mosquitoes which feed primarily on birds, but it can also be carried by the Asian Tiger mosquito, AEDES albopictus, which feeds mainly on mammals. Egypt 101 virus,Kunjin virus
D015967 Gene Expression Regulation, Viral Any of the processes by which cytoplasmic factors influence the differential control of gene action in viruses. Regulation of Gene Expression, Viral,Viral Gene Expression Regulation,Regulation, Gene Expression, Viral

Related Publications

O Reynard, and V Mokhonov, and E Mokhonova, and J Leung, and A Page, and M Mateo, and O Pyankova, and M C Georges-Courbot, and H Raoul, and A A Khromykh, and V E Volchkov
January 2012, PLoS neglected tropical diseases,
O Reynard, and V Mokhonov, and E Mokhonova, and J Leung, and A Page, and M Mateo, and O Pyankova, and M C Georges-Courbot, and H Raoul, and A A Khromykh, and V E Volchkov
June 1998, Virology,
O Reynard, and V Mokhonov, and E Mokhonova, and J Leung, and A Page, and M Mateo, and O Pyankova, and M C Georges-Courbot, and H Raoul, and A A Khromykh, and V E Volchkov
June 2008, Vaccine,
O Reynard, and V Mokhonov, and E Mokhonova, and J Leung, and A Page, and M Mateo, and O Pyankova, and M C Georges-Courbot, and H Raoul, and A A Khromykh, and V E Volchkov
May 2018, The Journal of infectious diseases,
O Reynard, and V Mokhonov, and E Mokhonova, and J Leung, and A Page, and M Mateo, and O Pyankova, and M C Georges-Courbot, and H Raoul, and A A Khromykh, and V E Volchkov
November 2019, Vaccine,
O Reynard, and V Mokhonov, and E Mokhonova, and J Leung, and A Page, and M Mateo, and O Pyankova, and M C Georges-Courbot, and H Raoul, and A A Khromykh, and V E Volchkov
October 2015, The Journal of infectious diseases,
O Reynard, and V Mokhonov, and E Mokhonova, and J Leung, and A Page, and M Mateo, and O Pyankova, and M C Georges-Courbot, and H Raoul, and A A Khromykh, and V E Volchkov
October 2015, The Journal of infectious diseases,
O Reynard, and V Mokhonov, and E Mokhonova, and J Leung, and A Page, and M Mateo, and O Pyankova, and M C Georges-Courbot, and H Raoul, and A A Khromykh, and V E Volchkov
November 2018, The Journal of infectious diseases,
O Reynard, and V Mokhonov, and E Mokhonova, and J Leung, and A Page, and M Mateo, and O Pyankova, and M C Georges-Courbot, and H Raoul, and A A Khromykh, and V E Volchkov
February 2004, Virology,
O Reynard, and V Mokhonov, and E Mokhonova, and J Leung, and A Page, and M Mateo, and O Pyankova, and M C Georges-Courbot, and H Raoul, and A A Khromykh, and V E Volchkov
December 2003, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!